Hartung HP - Search Results

1

Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.

Marignier R, Bennett JL, Kim HJ, Weinshenker BG, Pittock SJ, Wingerchuk D, Fujihara K, Paul F, Cutter GR, Green AJ, Aktas O, Hartung HP, Lublin FD, Williams IM, Drappa J, She D, Cimbora D, Rees W, Smith M, Ratchford JN, Katz E, Cree BAC; N-MOmentum Study Investigators. Marignier R, et al. Among authors: hartung hp. Neurol Neuroimmunol Neuroinflamm. 2021 Mar 26;8(3):e978. doi: 10.1212/NXI.0000000000000978. Print 2021 May. Neurol Neuroimmunol Neuroinflamm. 2021. PMID: 33771837 Free PMC article. Clinical Trial.

2

Characterizing the mechanisms of progression in multiple sclerosis: evidence and new hypotheses for future directions.

Frohman EM, Filippi M, Stuve O, Waxman SG, Corboy J, Phillips JT, Lucchinetti C, Wilken J, Karandikar N, Hemmer B, Monson N, De Keyser J, Hartung H, Steinman L, Oksenberg JR, Cree BA, Hauser S, Racke MK. Frohman EM, et al. Arch Neurol. 2005 Sep;62(9):1345-56. doi: 10.1001/archneur.62.9.1345. Arch Neurol. 2005. PMID: 16157741 Review.

3

Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations.

Frohman EM, Stüve O, Havrdova E, Corboy J, Achiron A, Zivadinov R, Sorensen PS, Phillips JT, Weinshenker B, Hawker K, Hartung HP, Steinman L, Zamvil S, Cree BA, Hauser S, Weiner H, Racke MK, Filippi M. Frohman EM, et al. Among authors: hartung hp. Arch Neurol. 2005 Oct;62(10):1519-30. doi: 10.1001/archneur.62.10.1519. Arch Neurol. 2005. PMID: 16216934 Review.

4

Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, Lublin FD, Metz LM, McFarland HF, O'Connor PW, Sandberg-Wollheim M, Thompson AJ, Weinshenker BG, Wolinsky JS. Polman CH, et al. Among authors: hartung hp. Ann Neurol. 2005 Dec;58(6):840-6. doi: 10.1002/ana.20703. Ann Neurol. 2005. PMID: 16283615 Review.

5

Neuromyelitis and more: the unfolding spectrum of aquaporin 4-related neurological diseases.

Aktas O, Hartung HP. Aktas O, et al. Among authors: hartung hp. J Neurol. 2009 Nov;256(11):1906-8. doi: 10.1007/s00415-009-5317-x. J Neurol. 2009. PMID: 19768482 No abstract available.

6

Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis.

Awad A, Hemmer B, Hartung HP, Kieseier B, Bennett JL, Stuve O. Awad A, et al. Among authors: hartung hp. J Neuroimmunol. 2010 Feb 26;219(1-2):1-7. doi: 10.1016/j.jneuroim.2009.09.002. Epub 2009 Sep 25. J Neuroimmunol. 2010. PMID: 19782408 Review.

7

Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope.

Hartung HP, Aktas O. Hartung HP, et al. Ann Neurol. 2009 Oct;66(4):429-32. doi: 10.1002/ana.21880. Ann Neurol. 2009. PMID: 19847907 No abstract available.

8

Development of oral cladribine for the treatment of multiple sclerosis.

Hartung HP, Aktas O, Kieseier B, Giancarlo Comi GC. Hartung HP, et al. J Neurol. 2010 Feb;257(2):163-70. doi: 10.1007/s00415-009-5359-0. J Neurol. 2010. PMID: 19921304 Review.

9

Neuroprotection, regeneration and immunomodulation: broadening the therapeutic repertoire in multiple sclerosis.

Aktas O, Kieseier B, Hartung HP. Aktas O, et al. Among authors: hartung hp. Trends Neurosci. 2010 Mar;33(3):140-52. doi: 10.1016/j.tins.2009.12.002. Epub 2010 Jan 4. Trends Neurosci. 2010. PMID: 20045200 Review.

10

Oral therapies for multiple sclerosis: are we there yet?

Hartung HP, Aktas O. Hartung HP, et al. Lancet Neurol. 2010 May;9(5):454-7. doi: 10.1016/S1474-4422(10)70088-0. Lancet Neurol. 2010. PMID: 20398852 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,122 results

Search Page